Donaldson Posts 5% Revenue Gain in Q4

Donaldson (NYSE:DCI) reported record Q4 FY2025 results, with revenue climbing 4.8% to $980.7 million and non-GAAP EPS rising 9.6% to $1.03, reflecting strong adjusted profitability and a 40% surge in free cash flow. Growth was notably driven by its Life Sciences (+14.1%) and Industrial Solutions (+7.7%) segments, despite a GAAP gross margin slip due to tariff pressures. The company provided an optimistic FY2026 outlook, projecting sales growth of 1-5% and expanding operating margins, underscoring operational discipline amidst ongoing cost and tariff headwinds.

Analysis

Donaldson (DCI) delivered record Q4 and full-year results for FY2025, characterized by solid top-line growth and strong cash generation, though profitability faced headwinds. Quarterly revenue increased 4.8% year-over-year to $980.7 million, while non-GAAP EPS grew 9.6% to $1.03, meeting but not significantly exceeding Wall Street estimates. The growth was uneven across segments, with the Life Sciences division posting standout performance with a 14.1% sales increase, and Industrial Solutions growing a healthy 7.7%. This strength offset the more modest 2.3% growth in the larger Mobile Solutions segment, which experienced significant weakness in the On-Road truck market that was balanced by resilience in aftermarket and off-road sales. A key point of concern is the contraction in GAAP gross margin, which fell to 34.5% from 35.8% due to tariff-related pressures and inventory dynamics, even as disciplined expense management kept non-GAAP operating margins stable. The company's financial health is underscored by a 40.0% surge in free cash flow to $149.7 million, enabling robust shareholder returns through a 4.0% share repurchase over the fiscal year and an 8.8% dividend increase. Looking to FY2026, management's guidance projects continued but moderated growth with sales up 1-5% and an EPS range of $3.92 to $4.08, alongside an expected expansion in operating margins to between 16.1% and 16.7%, indicating confidence in offsetting ongoing cost pressures.

Key Decisions for Investors

• Investors should monitor gross margin trends closely, as the company's ability to achieve its guided operating margin expansion for FY2026 is contingent on successfully managing persistent tariff and cost pressures.
• The diversification strategy is proving effective, but focus should be placed on the sustainability of the Life Sciences segment's growth, which is forecast to slow from 14.1% to 1-5%, and the continued resilience of the high-margin aftermarket business.
• Given the strong free cash flow and commitment to capital returns, DCI may be attractive for total-return investors, however, it is prudent to scrutinize the rising net debt and the effectiveness of capital deployment into new growth initiatives.